Literature DB >> 18025803

Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas.

Bert H O'Neil1, Petra Bůzková, Hillary Farrah, David Kashatus, Hanna Sanoff, Richard M Goldberg, Albert S Baldwin, William K Funkhouser.   

Abstract

PURPOSE: Nuclear factor-kappaB (NF-kappaB) has been shown to be abnormally activated in some human hepatocellular carcinomas (HCCs), but most studies of NF-kappaB in patient samples have focused on the p65 subunit. Recent information has implicated IkappaB family members (e.g. Bcl-3) as possible mediators of NF-kappaB activation. Therefore, we examined the expression of all NF-kappaB family members and downstream targets in HCC. STUDY
DESIGN: Archived HCCs from 30 patients were evaluated by immunohistochemistry for NF-kappaB family proteins, Bcl-3 and targets of NF-kappaB/IkappaB function. Results were validated by Western blotting in frozen paired HCC and adjacent normal tissue in a subset of cases.
RESULTS: NF-kappaB p50 and p52 subunits were frequently localized to tumor cell nuclei (40 and 48%), whereas p65 positivity was infrequent. Bcl-3 was overexpressed in 90% of tumor cell nuclei compared with 26% of adjacent non-neoplastic liver (p < 0.001).
CONCLUSIONS: Aberrant Bcl-3 nuclear expression occurs in the vast majority of HCCs compared with adjacent normal or cirrhotic liver tissue. Bcl-3 is known to interact with NF-kappaB p50 and p52 homodimers, and our study demonstrates very frequent nuclear colocalization of Bcl-3 and p50/p52, suggesting that the Bcl-3/p50 or Bcl-3/p52 interactions are important in HCC pathogenesis. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025803     DOI: 10.1159/000111116

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  17 in total

1.  The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.

Authors:  Aurore Keutgens; Kateryna Shostak; Pierre Close; Xin Zhang; Benoît Hennuy; Marie Aussems; Jean-Paul Chapelle; Patrick Viatour; André Gothot; Marianne Fillet; Alain Chariot
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

2.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

3.  Epigenetic Regulation in Breast Cancer.

Authors:  Hye Jin Nam; Sung Hee Baek
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA.

Authors:  Wei Wu; Dengfu Yao; Yilang Wang; Liwei Qiu; Wenli Sai; Junling Yang; Ninghua Yao; Shanshan Li; Yinzhu Bian; Zhiwei Wang; Dengbing Yao
Journal:  Tumour Biol       Date:  2010-07-14

5.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

Review 6.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

7.  BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1.

Authors:  Aurore Keutgens; Xin Zhang; Kateryna Shostak; Isabelle Robert; Sabine Olivier; Alain Vanderplasschen; Jean-Paul Chapelle; Patrick Viatour; Marie-Paule Merville; Françoise Bex; André Gothot; Alain Chariot
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

8.  The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter.

Authors:  Young-Mi Kim; Neelam Sharma; Jennifer K Nyborg
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

Review 9.  The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target.

Authors:  Yonghui Yu; Yu Wan; Chuanshu Huang
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

10.  Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.

Authors:  Yun Shi; Si-Ye Wang; Min Yao; Wen-Li Sai; Wei Wu; Jun-Ling Yang; Yin Cai; Wen-Jie Zheng; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.